Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation

被引：0
|
作者：
Ma, W. [1 ]
Gong, J. [1 ]
Shan, J. [2 ]
Lewis, D. [2 ]
Xiao, W. [3 ]
Hung, J. [4 ]
Moore, E. H. [5 ]
Zhang, Y. [6 ]
Mans, N. Z. [7 ]
Welborn, J. [5 ]
Lam, K. S. [3 ]
Li, T. [1 ]
机构：
[1] Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Sacramento, CA 95817 USA
[2] Albert Einstein Coll Med, Dept Genet, New York, NY USA
[3] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA
[4] Sierra Nevada Med Grp, Grass Valley, CA USA
[5] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA
[6] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA
[7] Univ Calif Davis, Hereditary Canc Program, Ctr Comprehens Canc, Sacramento, CA 95817 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
osimertinib; lung cancer; Germline EGFR T790M;
D O I：
10.1016/j.jtho.2017.09.590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 15.08
引用
收藏
页码：S1863 / S1864
页数：2
相关论文
共 50 条
  • [31] ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation
    Karachaliou, Niki
    Gimenez-Capitan, Ana
    Drozdowskyj, Ana
    Viteri, Santiago
    Moran, Teresa
    Carcereny, Enric
    Massuti, Bartomeu
    Vergnenegre, Alain
    de Marinis, Filippo
    Angel Molina, Miguel
    Teixido, Cristina
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (03) : 122 - 130
  • [32] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
    Oxnard, Geoffrey R.
    Arcila, Maria E.
    Sima, Camelia S.
    Riely, Gregory J.
    Chmielecki, Juliann
    Kris, Mark G.
    Pao, William
    Ladanyi, Marc
    Miller, Vincent A.
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1616 - 1622
  • [33] Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping
    Oxnard, Geoffrey R.
    Miller, Vincent A.
    Robson, Mark E.
    Azzoli, Christopher G.
    Pao, William
    Ladanyi, Marc
    Arcila, Maria E.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : 1049 - 1052
  • [34] Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer
    Kawamura, Takahisa
    Kenmotsu, Hirotsugu
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Omae, Katsuhiro
    Mori, Keita
    Tanigawara, Yusuke
    Nakajima, Takashi
    Ohde, Yasuhisa
    Endo, Masahiro
    Takahashi, Toshiaki
    CLINICAL LUNG CANCER, 2018, 19 (02) : E247 - E252
  • [35] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
  • [36] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [37] ROR1 AS A NOVEL THERAPEUTIC TARGET FOR EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH THE EGFR T790M MUTATION
    Karachaliou, Niki
    Drozdowskyj, Ana
    Costa, Carlota
    Angel Molina-Vila, Miguel
    Gimenez-Capitan, Ana
    Vergnenegre, Alain
    Massuti, Bartomeu
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Carcereny, Enric
    Garcia-Campelo, Rosario
    Viteri, Santiago
    Heidecke, Cordula
    Estrada-Tejedor, Roger
    Teixido, Jordi
    Bivona, Trever
    Giannikopoulos, Petros
    Ono, Mayumi
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1048 - S1048
  • [38] Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.
    Planchard, David
    Yu, Helena Alexandra
    Yang, James Chih-Hsin
    Lee, Ki Hyeong
    Lopez, Pilar Garrido
    Park, Keunchil
    Kim, Joo-Hang
    Lee, Dae Ho
    He, Shuang
    Chao, Bo H.
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M
    Senoo, Satoru
    Ohashi, Kadoaki
    Nishii, Kazuya
    Hara, Naofumi
    Kano, Hirohisa
    Ninomiya, Kiichiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E140 - E142
  • [40] Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
    Janjigian, Yelena Y.
    Smit, Egbert F.
    Groen, Harry J. M.
    Horn, Leora
    Gettinger, Scott
    Camidge, D. Ross
    Riely, Gregory J.
    Wang, Bushi
    Fu, Yali
    Chand, Vikram K.
    Miller, Vincent A.
    Pao, William
    CANCER DISCOVERY, 2014, 4 (09) : 1036 - 1045
12345